Cancer Discov. 2023 Feb 6;13(2):250-251. doi: 10.1158/2159-8290.CD-NB2022-0079.
Nearly three quarters of the 288 patients with relapsed/refractory multiple myeloma enrolled in the phase I/II MonumenTAL-1 trial of the investigational drug talquetamab experienced significant anticancer effects. A first-in-class, off-the-shelf bispecific antibody, talquetamab targets GPRC5D, which is highly expressed on malignant plasma cells but limited on normal cells, and recruits CD3-expressing T cells, activating an immune response.
在一项针对研究性药物talquetamab的I/II期MonumenTAL-1试验中，入组的288例复发/难治性多发性骨髓瘤患者中，近四分之三经历了显著的抗癌效果。Talquetamab是一种一流的现成双特异性抗体，靶向GPRC5D，该蛋白在恶性浆细胞上高度表达，但在正常细胞上表达有限，并招募表达CD3的T细胞，激活免疫反应。
